Pharmaceuticals

FDA expands indication of BioMarin’s Brineura to children with neuronal ceroid lipofuscinosis type 2

bexib
By bexib 0 Min Read

The expanded indication for Brineura allows for the treatment of neuronal ceroid lipofuscinosis type 2 in both symptomatic and pre-symptomatic children.

You Might Also Like

Three biotech hotspots in the US

FDA Issues Complete Response Letter to Lykos Therapeutics Regarding Midaphetamine Capsules for the Treatment of Post-Traumatic Stress Disorder

The rise of AI in pharmaceuticals

Empty shelves, emergency solution

Transforming Patient Care Management: Q&A with Dea Belazi

Share This Article
Previous Article More poverty for the poor
Next Article Dogecoin poised for 1,700% rally as it mirrors past cycles: Analyst – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Hyundai Motor India Limited to transport 26% of domestic sales volume by rail freight in 2024
Manufacturing
Chestnut Keeps Norfolk Momentum – Luxury Hospitality Magazine
Hospitality & Tourism
Valley Bank uses AI to reduce AML false positives by 65%
Banking
U.S. shipbuilding could accelerate this year
Manufacturing